Solvay spin-off Syensqo has signed a memorandum of understanding (MoU) with Allozymes, a Singaporean start-up specialising in enzyme bioengineering.
Allozymes has developed an ultra-high throughput microfluidics platform for the engineering of enzymes and microbes for personal and home care.
This platform, says Syensqo, enables the rapid and cost-effective development of biomanufactured ingredients and bioprocesses, setting a new standard for innovation and sustainability in the industry.
“By combining Allozymes technological capabilities with Syensqo's application and market access expertise, we are poised to create groundbreaking solutions that will not only benefit the home and personal care market but also contribute to a more sustainable future,” added Thomas Canova, head of Renewable Materials & Biotechnology growth platform at Syensqo.
Syensqo said the MoU fits with its strategic agenda of rapidly expanding its beauty speciality ingredients portfolio based on biotechnology.
It complements the company's recent acquisition of South Korean ceramides specialist JinYoung Bio, further solidifying its commitment to enabling sustainable and innovative care solutions.
“Our partnership with Syensqo embodies our mutual commitment to a sustainable future, leveraging biotechnology to enable cleaner, greener processes, ensuring our actions today contribute to a healthier planet for future generations,” said Peyman Salehian, CEO and co-founder of Allozymes.
